Background:Chronic pain is defined as pain that lasts for three months or even more.Over 25%of the global population suffers from chronic pain.Tong-luo Qu-tong(TLQT)Plaster is clinically used to treat arthritis.Howeve...Background:Chronic pain is defined as pain that lasts for three months or even more.Over 25%of the global population suffers from chronic pain.Tong-luo Qu-tong(TLQT)Plaster is clinically used to treat arthritis.However,its ability to treat chronic pain remains largely unknown.Methods:In this study,we explored the molecular mechanism of TLQT plaster in relieving chronic muscle pain by combining network pharmacology and RNA-seq analysis.We also applied the Elisa and the RT-qPCR.Results:We found 447 targets in TLQT and 13,599 targets related to chronic pain disease.And 419 intersecting targets were obtained,which mainly enrich the IL-17 signaling pathway,TNF signaling pathway,and Th17 cell differentiation pathway.Further,we constructed the SD rat model of chronic pain.The results of Von Frey Hair Test showed that the relief of muscle pain TLQT treated group was twice as much as that in the model group.The hot plate test results showed that the time of lifting the foot was 1.3 times as much as that of the model group.Moreover,TLQT effectively reduced the inflammation in rat muscle.With RNA-seq analysis,230 differentially expressed genes were collected.The RT-qPCR results indicated that the mRNA expression level of NCF1,CXCL10,and ICAM1 all promoted in the model group,and then decreased significantly in the TLQT treated group.The ELISA results performed that the level of IL-1βand IL-6 in TLQT group high dose group was reduced by about 1.6-fold,and for TNF-α,it was reduced by about 2.6-fold compared with the model group.Immunohistochemistry assay showed that the expression level of CXCL10 and ICAM1 was both up-regulated in the model group and down-regulated in the TLQT group.Conclusion:TLQT plaster reduces chronic muscle pain by inhibiting the expression of NCF1,CXCL10,and ICAM1 and reducing the level of muscle tissue inflammation.展开更多
目的分析2型糖尿病(T2DM)合并失眠患者血清细胞间黏附分子1(ICAM-1)、氧化型低密度脂蛋白(ox-LDL)及血管内皮生长因子(VEGF)水平的变化特征,探讨其临床意义。方法选取2021年5月至2022年5月某医院收治的108例T2DM患者,根据匹兹堡睡眠质...目的分析2型糖尿病(T2DM)合并失眠患者血清细胞间黏附分子1(ICAM-1)、氧化型低密度脂蛋白(ox-LDL)及血管内皮生长因子(VEGF)水平的变化特征,探讨其临床意义。方法选取2021年5月至2022年5月某医院收治的108例T2DM患者,根据匹兹堡睡眠质量指数(PSQI)评分分为无失眠组(PSQI≤7分,n=53)和失眠组(PSQI>7分,n=55)。比较两组一般临床特征、糖脂代谢指标及血清ICAM-1、ox-LDL、VEGF水平,并分析PSQI总分与各指标的相关性。结果失眠组收缩压、空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)、糖化血红蛋白(HbA1c)、总胆固醇(TC)水平显著高于无失眠组(P<0.05);失眠组血清ICAM-1(4.03±0.83 ng/mL vs 3.18±0.60 ng/mL)、ox-LDL(14.02±4.75μg/mL vs 9.97±4.05μg/mL)水平显著高于无失眠组(P均<0.05),而两组VEGF水平差异无统计学意义(P>0.05)。Pearson相关分析显示,PSQI总分与ICAM-1(r=0.52)、ox-LDL(r=0.46)呈正相关(P均<0.05)。结论T2DM合并失眠患者血清ICAM-1、ox-LDL水平显著升高,失眠可能通过加剧炎症反应和氧化应激,促进糖尿病微血管并发症的发生与发展。展开更多
文摘Background:Chronic pain is defined as pain that lasts for three months or even more.Over 25%of the global population suffers from chronic pain.Tong-luo Qu-tong(TLQT)Plaster is clinically used to treat arthritis.However,its ability to treat chronic pain remains largely unknown.Methods:In this study,we explored the molecular mechanism of TLQT plaster in relieving chronic muscle pain by combining network pharmacology and RNA-seq analysis.We also applied the Elisa and the RT-qPCR.Results:We found 447 targets in TLQT and 13,599 targets related to chronic pain disease.And 419 intersecting targets were obtained,which mainly enrich the IL-17 signaling pathway,TNF signaling pathway,and Th17 cell differentiation pathway.Further,we constructed the SD rat model of chronic pain.The results of Von Frey Hair Test showed that the relief of muscle pain TLQT treated group was twice as much as that in the model group.The hot plate test results showed that the time of lifting the foot was 1.3 times as much as that of the model group.Moreover,TLQT effectively reduced the inflammation in rat muscle.With RNA-seq analysis,230 differentially expressed genes were collected.The RT-qPCR results indicated that the mRNA expression level of NCF1,CXCL10,and ICAM1 all promoted in the model group,and then decreased significantly in the TLQT treated group.The ELISA results performed that the level of IL-1βand IL-6 in TLQT group high dose group was reduced by about 1.6-fold,and for TNF-α,it was reduced by about 2.6-fold compared with the model group.Immunohistochemistry assay showed that the expression level of CXCL10 and ICAM1 was both up-regulated in the model group and down-regulated in the TLQT group.Conclusion:TLQT plaster reduces chronic muscle pain by inhibiting the expression of NCF1,CXCL10,and ICAM1 and reducing the level of muscle tissue inflammation.
文摘目的分析2型糖尿病(T2DM)合并失眠患者血清细胞间黏附分子1(ICAM-1)、氧化型低密度脂蛋白(ox-LDL)及血管内皮生长因子(VEGF)水平的变化特征,探讨其临床意义。方法选取2021年5月至2022年5月某医院收治的108例T2DM患者,根据匹兹堡睡眠质量指数(PSQI)评分分为无失眠组(PSQI≤7分,n=53)和失眠组(PSQI>7分,n=55)。比较两组一般临床特征、糖脂代谢指标及血清ICAM-1、ox-LDL、VEGF水平,并分析PSQI总分与各指标的相关性。结果失眠组收缩压、空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)、糖化血红蛋白(HbA1c)、总胆固醇(TC)水平显著高于无失眠组(P<0.05);失眠组血清ICAM-1(4.03±0.83 ng/mL vs 3.18±0.60 ng/mL)、ox-LDL(14.02±4.75μg/mL vs 9.97±4.05μg/mL)水平显著高于无失眠组(P均<0.05),而两组VEGF水平差异无统计学意义(P>0.05)。Pearson相关分析显示,PSQI总分与ICAM-1(r=0.52)、ox-LDL(r=0.46)呈正相关(P均<0.05)。结论T2DM合并失眠患者血清ICAM-1、ox-LDL水平显著升高,失眠可能通过加剧炎症反应和氧化应激,促进糖尿病微血管并发症的发生与发展。
